| # | Title | Journal | Year | Citations |
|---|
| 1 | Decreased extra-renal urate excretion is a common cause of hyperuricemia | Nature Communications | 2012 | 489 |
| 2 | Coupling of bone resorption and formation by RANKL reverse signalling | Nature | 2018 | 376 |
| 3 | Common Defects of ABCG2, a High-Capacity Urate Exporter, Cause Gout: A Function-Based Genetic Analysis in a Japanese Population | Science Translational Medicine | 2009 | 334 |
| 4 | Serum metabolomics reveals γ-glutamyl dipeptides as biomarkers for discrimination among different forms of liver disease | Journal of Hepatology | 2011 | 217 |
| 5 | Plasma concentration profiles of ketamine and norketamine after administration of various ketamine preparations to healthy Japanese volunteers | Biopharmaceutics and Drug Disposition | 2003 | 168 |
| 6 | Genome-wide association study of clinically defined gout identifies multiple risk loci and its association with clinical subtypes | Annals of the Rheumatic Diseases | 2016 | 144 |
| 7 | General Framework for the Quantitative Prediction of CYP3A4-Mediated Oral Drug Interactions Based on the AUC Increase by Coadministration of??Standard Drugs | Clinical Pharmacokinetics | 2007 | 140 |
| 8 | Niemann-Pick C1-Like 1 Mediates α-Tocopherol Transport | Molecular Pharmacology | 2008 | 128 |
| 9 | ABCG2 dysfunction causes hyperuricemia due to both renal urate underexcretion and renal urate overload | Scientific Reports | 2014 | 125 |
| 10 | Comparative analysis of buprenorphine- and norbuprenorphine-induced analgesic effects based on pharmacokinetic-pharmacodynamic modeling | Journal of Pharmacology and Experimental Therapeutics | 1995 | 117 |
| 11 | Niemann-Pick C1-Like 1 Overexpression Facilitates Ezetimibe-Sensitive Cholesterol and β-Sitosterol Uptake in CaCo-2 Cells | Journal of Pharmacology and Experimental Therapeutics | 2007 | 116 |
| 12 | GWAS of clinically defined gout and subtypes identifies multiple susceptibility loci that include urate transporter genes | Annals of the Rheumatic Diseases | 2017 | 114 |
| 13 | Two common PFIC2 mutations are associated with the impaired membrane trafficking of BSEP/ABCB11 | Hepatology | 2005 | 113 |
| 14 | Common dysfunctional variants in ABCG2 are a major cause of early-onset gout | Scientific Reports | 2013 | 105 |
| 15 | Pharmacokinetic profile of glycyrrhizin in healthy volunteers by a new high‐performance liquid chromatographic method | Journal of Pharmaceutical Sciences | 1992 | 101 |
| 16 | Inhibitors of Human ABCG2: From Technical Background to Recent Updates With Clinical Implications | Frontiers in Pharmacology | 2019 | 99 |
| 17 | Japanese antimicrobial consumption surveillance: First report on oral and parenteral antimicrobial consumption in Japan (2009–2013) | Journal of Global Antimicrobial Resistance | 2016 | 97 |
| 18 | Determination of erythromycin, clarithromycin, roxithromycin, and azithromycin in plasma by high-performance liquid chromatography with amperometric detection | Biomedical Applications | 2000 | 96 |
| 19 | General Framework for the Prediction of Oral Drug Interactions Caused by CYP3A4 Induction from In Vivo Information | Clinical Pharmacokinetics | 2008 | 96 |
| 20 | Kinetics of respiratory depression in rats induced by buprenorphine and its metabolite, norbuprenorphine | Journal of Pharmacology and Experimental Therapeutics | 1997 | 94 |
| 21 | Identification of Febuxostat as a New Strong ABCG2 Inhibitor: Potential Applications and Risks in Clinical Situations | Frontiers in Pharmacology | 2016 | 93 |
| 22 | RANKL subcellular trafficking and regulatory mechanisms in osteocytes | Journal of Bone and Mineral Research | 2013 | 88 |
| 23 | Prediction of pharmacokinetic drug–drug interaction caused by changes in cytochrome P450 activity using in vivo information | | 2010 | 87 |
| 24 | NPC1L1 is a key regulator of intestinal vitamin K absorption and a modulator of warfarin therapy | Science Translational Medicine | 2015 | 82 |
| 25 | Modeling of Rifampicin-Induced CYP3A4 Activation Dynamics for the Prediction of Clinical Drug-Drug Interactions from In Vitro Data | PLoS ONE | 2013 | 78 |
| 26 | Itraconazole-Induced Cholestasis: Involvement of the Inhibition of Bile Canalicular Phospholipid Translocator MDR3/ABCB4 | Molecular Pharmacology | 2011 | 74 |
| 27 | Genome-wide association study revealed novel loci which aggravate asymptomatic hyperuricaemia into gout | Annals of the Rheumatic Diseases | 2019 | 73 |
| 28 | Effect of the single CYP2C9*3 allele on pharmacokinetics and pharmacodynamics of losartan in healthy Japanese subjects | European Journal of Clinical Pharmacology | 2003 | 72 |
| 29 | ABCG2 is a High-Capacity Urate Transporter and its Genetic Impairment Increases Serum Uric Acid Levels in Humans | Nucleosides, Nucleotides and Nucleic Acids | 2011 | 70 |
| 30 | Common dysfunctional variants of ABCG2 have stronger impact on hyperuricemia progression than typical environmental risk factors | Scientific Reports | 2014 | 70 |
| 31 | Comparative Pharmacodynamic Analysis of Q-T Interval Prolongation Induced by the Macrolides Clarithromycin, Roxithromycin, and Azithromycin in Rats | Antimicrobial Agents and Chemotherapy | 2000 | 66 |
| 32 | Comparative Pharmacodynamics of Eight Calcium Channel Blocking Agents in Japanese Essential Hypertensive Patients. | Biological and Pharmaceutical Bulletin | 1996 | 60 |
| 33 | Regulatory Mechanisms of RANKL Presentation to Osteoclast Precursors | Current Osteoporosis Reports | 2014 | 60 |
| 34 | ABCG2 Dysfunction Increases Serum Uric Acid by Decreased Intestinal Urate Excretion | Nucleosides, Nucleotides and Nucleic Acids | 2014 | 60 |
| 35 | Prediction of midazolam-CYP3A inhibitors interaction in the human liver from in vivo/in vitro absorption, distribution, and metabolism data | Drug Metabolism and Disposition | 2001 | 59 |
| 36 | Comparative pharmacokinetic/pharmacodynamic analysis of proton pump inhibitors omeprazole, lansoprazole and pantoprazole, in humans | European Journal of Drug Metabolism and Pharmacokinetics | 1998 | 53 |
| 37 | Oxidative stress and Mrp2 internalization | Free Radical Biology and Medicine | 2006 | 53 |
| 38 | Oxidative stress and enhanced paracellular permeability in the small intestine of methotrexate-treated rats | Cancer Chemotherapy and Pharmacology | 2010 | 53 |
| 39 | Pharmacokinetic analysis of enterohepatic circulation of buprenorphine and its active metabolite, norbuprenorphine, in rats | Drug Metabolism and Disposition | 1994 | 52 |
| 40 | HNF4α is a Crucial Modulator of the Cholesterol-Dependent Regulation of NPC1L1 | Pharmaceutical Research | 2008 | 50 |
| 41 | NPC2 Regulates Biliary Cholesterol Secretion via Stimulation of ABCG5/G8-Mediated Cholesterol Transport | Gastroenterology | 2011 | 49 |
| 42 | Comparison of the hepatic uptake clearances of fifteen drugs with a wide range of membrane permeabilities in isolated rat hepatocytes and perfused rat livers | Pharmaceutical Research | 1993 | 48 |
| 43 | A common missense variant of monocarboxylate transporter 9 (MCT9/SLC16A9) gene is associated with renal overload gout, but not with all gout susceptibility | Human Cell | 2013 | 48 |
| 44 | Functional identification of SLC43A3 as an equilibrative nucleobase transporter involved in purine salvage in mammals | Scientific Reports | 2015 | 47 |
| 45 | Quantitative relationship between myocardial concentration of tacrolimus and QT prolongation in guinea pigs: pharmacokinetic/pharmacodynamic model incorporating a site of adverse effect | Journal of Pharmacokinetics and Pharmacodynamics | 2001 | 46 |
| 46 | Molecular mechanisms of membrane transport of vitamin E | Molecular Nutrition and Food Research | 2010 | 46 |
| 47 | Multiple common and rare variants of ABCG2 cause gout | RMD Open | 2017 | 46 |
| 48 | Functional Characterization of Clinically-Relevant Rare Variants in ABCG2 Identified in a Gout and Hyperuricemia Cohort | Cells | 2019 | 46 |
| 49 | VLDL/LDL acts as a drug carrier and regulates the transport and metabolism of drugs in the body | Scientific Reports | 2017 | 45 |
| 50 | Identification of ABCG2 as an Exporter of Uremic Toxin Indoxyl Sulfate in Mice and as a Crucial Factor Influencing CKD Progression | Scientific Reports | 2018 | 45 |
